98 related articles for article (PubMed ID: 28211562)
1. Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.
Molica M; Breccia M; Colafigli G; Massaro F; Quattrocchi L; Mancini M; Diverio D; Latagliata R; Foà R
Br J Haematol; 2018 Apr; 181(2):275-278. PubMed ID: 28211562
[No Abstract] [Full Text] [Related]
2. Imatinib resistance due to a novel and rare class of mutation at position S348 (1043nt C→A) of Bcr/Abl gene in a chronic myeloid leukemia patient.
Dhangar S; C SK; S C; Vundinti BR
Leuk Res; 2018 Sep; 72():96-98. PubMed ID: 30118898
[No Abstract] [Full Text] [Related]
3. Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion.
Crampe M; Garry J; Langabeer SE; Murphy PT
Hematol Oncol Stem Cell Ther; 2016 Dec; 9(4):168-169. PubMed ID: 27352262
[No Abstract] [Full Text] [Related]
4. Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.
Moro MI; Manrique G; Uriarte R; Díaz L
Leuk Lymphoma; 2014 Jul; 55(7):1684-6. PubMed ID: 24083818
[No Abstract] [Full Text] [Related]
5. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
6. Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.
Klil-Drori AJ; Yin H; Azoulay L; Harnois M; Gratton MO; Del Corpo A; Olney HJ; Delage R; Laneuville P; Mollica L; Busque L; Assouline SE;
Am J Hematol; 2017 Oct; 92(10):E602-E604. PubMed ID: 28670773
[No Abstract] [Full Text] [Related]
7. Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
Kim SH; Kim D; Kim DW; Goh HG; Jang SE; Lee J; Kim WS; Kweon IY; Park SH
Hematol Oncol; 2009 Dec; 27(4):190-7. PubMed ID: 19274615
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
Bee PC; Sekaran V; Ng RR; Kweh TY; Gan GG
Singapore Med J; 2017 Mar; 58(3):150-154. PubMed ID: 27029807
[TBL] [Abstract][Full Text] [Related]
9. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
[TBL] [Abstract][Full Text] [Related]
10. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
[TBL] [Abstract][Full Text] [Related]
11. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
[TBL] [Abstract][Full Text] [Related]
12. Isolated polyglobulia as an uncommon presentation of chronic myeloid leukaemia.
Fozza C; Bonfigli S; Longu F; Pardini S; Dore F
Blood Cells Mol Dis; 2016 Jan; 56(1):37. PubMed ID: 26603721
[No Abstract] [Full Text] [Related]
13. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
[TBL] [Abstract][Full Text] [Related]
14. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Roy M; Sarkar R; Mukherjee A; Mukherjee S
Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
[TBL] [Abstract][Full Text] [Related]
16. Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
Chahardouli B; Zaker F; Mousavi SA; Saffari Z; Nadali F; Ostadali M; Ghadimi H; Alimoghaddam K; Ghavamzade A; Rostami S
Hematology; 2013 Nov; 18(6):328-33. PubMed ID: 23676790
[TBL] [Abstract][Full Text] [Related]
17. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
[TBL] [Abstract][Full Text] [Related]
18. Hematologic, liver enzymes and electrolytes changes in chronic myeloid leukemia after Imatinib medication.
Moshfeghi K; Nazemizadeh N; Mehrzad V; Hajiannejad A; Esmaeili F; Mohammadbeigi A
Indian J Cancer; 2015; 52(3):305-7. PubMed ID: 26905120
[TBL] [Abstract][Full Text] [Related]
19. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
20. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
